Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity. - Wikidata - awgldk - TriplyDB

Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.

Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.

http://www.wikidata.org/entity/Q37322304

about

Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models MUC1 and metastatic cancer: expression, function and therapeutic targeting.Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy.Update on Mucin-1 immunotherapy in cancer: a clinical perspective.Immunotherapy and tumor microenvironment Delivering safer immunotherapies for cancer.The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer.Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.

P2860

Q33961477-C9929E11-AE6B-4EA6-8BE9-B381A5CEAEC0 Q36827406-DCAA6359-7406-4562-A51C-DBEE18DA053C Q37636939-25F69774-3219-40ED-A58B-9AC085DFC237 Q38142315-1AB32020-2C17-416E-AFDD-5943483236E3 Q38603410-081C7FC7-9161-412B-A8BF-DD6689A22FBB Q38610306-807CB710-EFEA-415F-A3C0-5BA6BD05CD1D Q39330984-5CCAE8AA-DD59-43E6-8139-74E064B0B33C Q41233846-E0926031-1D9E-413C-9C8E-7A60861452ED Q47104633-DC4226CB-D772-4CA1-8C8A-E933FBC2016F Q51036586-29C617DA-1B04-4B96-BD50-0DC3865D6446

P2860

Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.

http://www.wikidata.org/entity/Q37322304

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 April 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Intratumoral delivery of CpG-c ...... s NK cell anti-tumor activity.

@en

Intratumoral delivery of CpG-c ...... s NK cell anti-tumor activity.

@nl

type

label

Intratumoral delivery of CpG-c ...... s NK cell anti-tumor activity.

@en

Intratumoral delivery of CpG-c ...... s NK cell anti-tumor activity.

@nl

prefLabel

Intratumoral delivery of CpG-c ...... s NK cell anti-tumor activity.

@en

Intratumoral delivery of CpG-c ...... s NK cell anti-tumor activity.

@nl

P1433

Q37322304-D52B7541-42E4-4D7C-86B1-73DF57EFB017

P1476

Q37322304-A356BDEA-16AF-4350-B9CC-0934E995D826

P2093

Q37322304-3837E69D-D39F-47D8-AD7F-3E567B9B3236

Q37322304-4F177512-F533-49E1-A898-658F56A1B019

Q37322304-8DE56345-83E6-4233-B12B-9BE6B608288C

Q37322304-8E825109-5396-4543-AFE8-7E83CD1F284E

Q37322304-B6211D1E-F348-4CA0-841E-7859CD5301A8

Q37322304-D758F68F-E035-4759-885C-882391AD91CE

Q37322304-EF10971B-E72D-4F37-8171-B66088DB00BC

Q37322304-F6A3B154-9DE4-4BA8-AEA6-6B8FF16AD40E

P2860

Q37322304-0023AD72-513B-4BCF-A3AA-B54362A04B09

Q37322304-01E17AE5-0926-454E-8E9A-29AF7800DE49

Q37322304-056847DD-991C-4025-AC6B-38EAB4EDEC96

Q37322304-05EC3DBD-EB98-449C-B5FD-2FB6FDAE008F

Q37322304-13B506D1-12D0-4490-B73F-A86A7FDB366E

Q37322304-15BFB213-1672-48CC-9AFC-D18226E6603F

Q37322304-1839611C-404A-4DD1-9E1B-333C3A656F3C

Q37322304-1A67808E-9842-467E-9F33-D892211843C4

Q37322304-1B1BABD1-2EBE-44FE-8305-D3590F5F613A

Q37322304-216C0127-8BED-44D4-BA5C-73294A8B04E5

P2888

Q37322304-495193ED-BA50-4C55-9D5E-E23B4B123F1A

P304

Q37322304-6A7F59EE-37B3-4E4D-96CE-034D09B433FF

P31

Q37322304-561F57CD-1C14-44AF-8A0C-8E61879020BA

P356

Q37322304-F39E955A-0CAE-4299-8260-5AC601D3B017

P433

Q37322304-83917AD6-9257-41BA-9289-88BEA8AD8DDB

P478

Q37322304-CADCB4E2-86BF-4FF8-AC37-0472987A2ED8

P577

Q37322304-EE7D5F0A-88CB-40B5-9C0A-4CF09371D90E

P698

Q37322304-62D6BF77-DF76-41DB-838F-94DAF5FD78C7

P932

Q37322304-DC57EC95-5199-4B24-8349-026A07E54ED6

P356

S00262-012-1264-Y

P1433

Cancer Immunology, Immunotherapy

P1476

Intratumoral delivery of CpG-c ...... s NK cell anti-tumor activity.

@en

P2093

Amritha Kidiyoor

http://www.w3.org/2001/XMLSchema#string

Dahlia M Besmer

http://www.w3.org/2001/XMLSchema#string

Jorge Schettini

http://www.w3.org/2001/XMLSchema#string

Joseph Lustgarten

http://www.w3.org/2001/XMLSchema#string

Lopamudra Das Roy

http://www.w3.org/2001/XMLSchema#string

Pinku Mukherjee

http://www.w3.org/2001/XMLSchema#string

Sandra J Gendler

http://www.w3.org/2001/XMLSchema#string

Teresa L Tinder

http://www.w3.org/2001/XMLSchema#string

P2860

MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

IgG Fc receptors

Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.

Interleukin 15: biology and relevance to human disease.

CpG motifs in bacterial DNA and their immune effects.

Ig-binding receptors on human NK cells as effector and regulatory surface molecules.

P2888

s00262-012-1264-y

P304

2055-2065

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-012-1264-Y

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22543528

http://www.w3.org/2001/XMLSchema#string

P932

3832960

http://www.w3.org/2001/XMLSchema#string